aTyr Pharma, Inc.
aTyr Pharma, Inc. (ATYR) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
atyr · stock forecast · 10 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Hold
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$17.00
Consensus
$5.13
+1060.4% upside
Low
$1.00
Median: $1.25 · Last Close: $0.44
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.42 | ↓ 5.00% |
1-day model range: $0.41–$0.43. Peak: $0.43 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ATYR · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-20 | Freedom Broker | Upgrade ↑ | Hold→Buy |
| 2025-11-07 | RBC Capital | Maintains | Sector Perform→Sector Perform |
| 2025-09-16 | Wells Fargo | Downgrade ↓ | Overweight→Equal Weight |
| 2025-09-16 | RBC Capital | Downgrade ↓ | Outperform→Sector Perform |
| 2025-09-15 | Cantor Fitzgerald | Downgrade ↓ | Overweight→Neutral |
| 2025-09-15 | LUCID CAPITAL MARKETS | Downgrade ↓ | Buy→Neutral |
| 2025-09-15 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-09-15 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2025-09-15 | Jones Trading | Downgrade ↓ | Buy→Hold |
| 2025-08-22 | Jefferies | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on aTyr Pharma, Inc. (ATYR) stock. Of the recent 27 rating actions, 1 were upgrades and 7 were downgrades. 10 analysts currently cover ATYR.
Analyst Recommendation Trends
ATYR analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$4M
↓ 90.8% YoY
Revenue Next Year
$9M
↑ 127.9% YoY
EPS This Year
$-0.57
EPS Next Year
$-0.62
↑ 8.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast ATYR EPS of $-0.57 for the current fiscal year, based on estimates from 4 analysts. The ATYR revenue forecast is $4M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ATYR stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ATYR price target is $5.13 (+1060.4% upside), with an analyst consensus of Hold.
The ATYR short-term stock prediction for tomorrow is $0.42 (-5.00%).
aTyr Pharma, Inc. trades on NASDAQ under the ticker ATYR. The ATYR stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 30% of covering analysts.
Frequently asked questions
ATYR forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month ATYR price target is $5.13, with a high forecast of $17.00 and a low of $1.00. The median price target is shown in the chart above when available. This implies +1060.4% potential upside from the current price of $0.44.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.